Register  /  Login               
Print this article
- 01/17/2018

Positive Keytruda lung cancer data for Merck

Pharma Horizon

Merck announced positive results its blockbuster drug Keytruda: a cocktail of immunotherapy Keytruda and two chemotherapy medicines helped lung cancer patients live longer and stopped the disease from advancing, early results from a study showed.
 The results will be presented at an upcoming medical meeting whose date and location were not announced.

The latest results cement Merck’s position as a front-runner in the race to develop drugs that can be used as the initial or first-line treatment for patients with a common type of lung cancer.

The results “will allow for Merck to extend their leadership position in 1st line non-small cell lung cancer where they are already dominating in the 25-30 percent of patients” whose tumors have high levels of PDL1, a protein targeted by the drug, Credit Suisse analyst Vamil Divan said in a research note.

They also increase the chances of a European regulatory approval, after Merck withdrew an application when regulators asked for more data, several analysts said.

 

Read further on Reuters website




About us



tks | publisher, event organiser,
media agency

Viale Brianza, 22
20127 - Milano - Italy

info@teknoscienze.com
Tel. +39 02 26809375